Below is a list of select startups that are tenants in the Venture Accelerator utilizing the expertise and full suite of business services of Tech Transfer’s Venture Center.
Transdermal bio sensor for alcohol and drug monitoring for court-mandated programs and other applications
CubeWorks has been leading revolutionary advances in ultra-low power computing through its CubiSens™ platform, the first truly autonomous wireless sensing platform in a millimeter-scale footprint.
Elegus is commercializing an aramid-based, ultra-strong battery separator made from high-performance nano-scale fibers. We believe our separator is thin and strong enough to enable lithium-ion batteries to increase energy density without compromising safety
Endectra LLC is commercializing solid-state, real-time radiation detection technology to displace expensive crystal- and gas-based sensors in defense, industrial, and medical applications.
The G-HMRC will provide health risk assessment (HRA) services and products as a multi-channel intelligent communication tool for health management decision support and will continue to advance our offerings through ongoing research and technology developments.
Risk evaluation tool uses your personal and family health history to find out if you are at increased risk for hereditary disease using easy-to-read report with next-step recommendations helps you and your doctor make a care plan to reduce your risk
Mekanistic Therapeutics designs and discovers anti-cancer agents that inhibit multiple cancer drivers. Our lead agent, MTX-211 is a potent and selective dual inhibitor of two frequently aberrant cancer drivers. It is effective against a number of cancer types generally resistant to monotherapy alone.
Designs neural network inference chips with unparalleled energy efficiency and compute density for edge computing, IoT, mobile, and more
Handheld MEMS-based VOC sensor system capable of detecting 20 VOC gases simultaneously
FAS apoptosis inhibitors to protect photoreceptors and preserve patient vision from retinal diseases. ONL is focused on preventing the death of key retinal cells, including photoreceptors—the root cause of vision loss and the leading cause of blindness.
Therapeutic monoclonal antibody for pulmonary fibrosis/asthma/fibrotic lung disease